RxDoctor Payments DataLook up a doctor →

Philip Ruzbarsky, MD

General Practice · Westminster, MDNPI 1225097058

Payments from drug & device makers

$17,873in general payments, 2019–2025

Across 1,082 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$840
  • Lundbeck LLC$822
  • plus $10K from 50 others

What the payments were for

  • Food & beverage$17,67899%
  • Education$1951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)181$2,655
Novo Nordisk116$1,583
AstraZeneca(2 entities)70$1,197
Lilly USA, LLC66$1,097
Amgen46$840
Lundbeck LLC38$822
Pfizer41$795
Axsome Therapeutics, Inc.29$575
Amarin Pharma, Inc.35$559
Orexo US, Inc.32$531
Johnson & Johnson55$528
Sanofi-aventis U.S. LLC27$470
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$468
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)22$450
Takeda Pharmaceuticals U.S.A., Inc.23$437
Bayer19$387
Harmony Biosciences LLC16$373
Biohaven Pharmaceutical Holding Company Ltd.17$342
Boehringer Ingelheim19$328
Gilead17$288
Merck18$284
Indivior Inc.15$262
GSK15$260
Exact Sciences9$217
Esperion Therapeutics, Inc.10$209
Biohaven Pharmaceuticals, Inc.10$197
Kowa Pharmaceuticals America, Inc.17$160
Antares Pharma, Inc.9$157
Idorsia Pharmaceuticals US Inc8$155
Otsuka America Pharmaceutical, Inc.7$121
Daiichi Sankyo Inc.6$115
Astellas Pharma US Inc6$107
Teva Pharmaceuticals USA, Inc.7$106
Jazz Pharmaceuticals Inc.4$74
Abbott3$67
Alkermes, Inc.3$66
Supernus Pharmaceuticals, Inc.4$64
Xeris Pharmaceuticals, Inc.2$61
Mylan Specialty L.p.3$54
Ironwood Pharmaceuticals, Inc3$47
Aimmune Therapeutics, Inc.2$40
Halozyme Inc2$38
Vanda Pharmaceuticals Inc.2$33
Acerus Pharmaceuticals Corporation2$29
Dexcom, Inc.1$25
Eisai Inc.1$24
Medtronic1$23
Cranial Technologies, Inc1$20
Medicomp Inc1$20
Collegium Pharmaceutical, Inc.1$19
Biodelivery Sciences International, Inc.1$18
Redhill Biopharma Inc.1$18
TMS Neurohealth Centers Inc.1$17
Exeltis, USA Inc.1$15
Braeburn Inc.1$15
Bausch Health US, LLC1$13

How this compares

$17,873 in reported general payments places this provider in the 95th percentile of 1,843 general practice providers in Maryland.

See all general practice providers in Maryland

Medicare billing

Part B allowed, 2024
$100,780
Medicare patients
344
Services billed
1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$125,067
JardianceEmpagliflozin82$119,545
MounjaroTirzepatide81$103,918
TrulicityDulaglutide37$78,282
XifaxanRifaximin16$69,376
CreonLipase/Protease/Amylase17$67,536
FarxigaDapagliflozin Propanediol41$56,416
Repatha SureclickEvolocumab34$49,278
XareltoRivaroxaban25$40,908
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$25,379
EliquisApixaban17$24,900
Soliqua 100-33Insulin Glargine/Lixisenatide17$22,326
JanuviaSitagliptin Phosphate15$21,555
Tresiba Flextouch U-200Insulin Degludec20$19,692
KerendiaFinerenone11$16,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,097$182,199118 claims
Novo NordiskOzempic$1,583$125,06751 claims
Boehringer IngelheimJardiance$328$119,54582 claims
AbbVieCreon, Synthroid$2,655$69,78850 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$468$69,37616 claims
AstraZenecaFarxiga, Symbicort$1,197$61,93755 claims
Johnson & JohnsonXarelto$528$40,90825 claims
GSKTrelegy Ellipta, Anoro Ellipta$260$30,85438 claims
PfizerEliquis$795$24,90017 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$470$22,32617 claims
MerckJanuvia$284$21,55515 claims
BayerKerendia$387$16,41211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,843 general practice providers in Maryland.

Other general practice in Westminster

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →